Ono Pharmaceutical Co (TSE:4528) Cash And Cash Equivalents : 円166,141 Mil (As of Mar. 2024)

View and export this data going back to 1963. Start your Free Trial

What is Ono Pharmaceutical Co Cash And Cash Equivalents?

Ono Pharmaceutical Co's quarterly cash and cash equivalents declined from Sep. 2023 (円107,704.00 Mil) to Dec. 2023 (円102,247.00 Mil) but then increased from Dec. 2023 (円102,247.00 Mil) to Mar. 2024 (円166,141.00 Mil).

Ono Pharmaceutical Co's annual cash and cash equivalents increased from Mar. 2022 (円69,112.00 Mil) to Mar. 2023 (円96,135.00 Mil) and increased from Mar. 2023 (円96,135.00 Mil) to Mar. 2024 (円166,141.00 Mil).

Ono Pharmaceutical Co Cash And Cash Equivalents Historical Data

The historical data trend for Ono Pharmaceutical Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ono Pharmaceutical Co Cash And Cash Equivalents Chart

Ono Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash And Cash Equivalents

Get a 7-Day Free Trial

69,005.00

61,045.00

69,112.00

96,135.00

166,141.00

Ono Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															96,135.00	60,433.00	107,704.00	102,247.00	166,141.00

Ono Pharmaceutical Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Ono Pharmaceutical Co (TSE:4528) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Ono Pharmaceutical Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Ono Pharmaceutical Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Ono Pharmaceutical Co (TSE:4528) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (TSE:4528) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

OPHLY:USA OPHLF:USA ON4:Germany

Address

8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564

Website

http://www.ono.co.jp

Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a global business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.

Ono Pharmaceutical Co (TSE:4528) Headlines

No Headlines